Biomind Labs (3XI) Stock Overview
A biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
3XI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Biomind Labs Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.38 |
| 52 Week High | US$0.43 |
| 52 Week Low | US$0.0005 |
| Beta | 7.26 |
| 1 Month Change | 21.79% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 251.85% |
| 5 Year Change | -69.45% |
| Change since IPO | -68.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3XI | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 6.7% | -2.0% | -1.5% |
| 1Y | n/a | 40.8% | 4.0% |
Return vs Industry: Insufficient data to determine how 3XI performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 3XI performed against the German Market.
Price Volatility
| 3XI volatility | |
|---|---|
| 3XI Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 3XI's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 3XI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Alejandro Antalich | www.biomindlabs.com |
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine sublingual formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s disease; BMND06 is in Phase I clinical trial for treatment of morbid obesity; and BMDO9 is in Phase I clinical trial for treatment of Parkinson’s disease. It is also developing preclinical drug candidates, including BMND02 for the treatment of fibromyalgia; BMND03 for the treatment of addictive disorders; BMND05 to treat chronic pain; and BMND07 for the treatment of major depressive disorder.
Biomind Labs Inc. Fundamentals Summary
| 3XI fundamental statistics | |
|---|---|
| Market cap | €16.74m |
| Earnings (TTM) | -€1.25m |
| Revenue (TTM) | n/a |
Is 3XI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3XI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.45m |
| Earnings | -US$1.45m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.019 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -43.6% |
How did 3XI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 12:22 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biomind Labs Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.